Silver Lining Outreach, Inc

The Arthur Ashe Institute for Urban Health, founded in 1992 by tennis legend Arthur Ashe, is dedicated to addressing health disparities in urban communities through innovative health education programs and research initiatives. The Institute honors individuals and organizations that significantly contribute to urban health, education, medical research, community service, and philanthropy through its annual SportsBall gala. With a mission to champion health equity and community wellness, the Institute focuses on preventing diseases such as diabetes and hypertension, which disproportionately affect urban populations due to inadequate healthcare delivery and education. Events like SportsBall not only celebrate achievements in these areas but also raise crucial funds to support the Institute's ongoing efforts in improving community health outcomes. Generated from the website

Mirimus, Inc. is a Brooklyn-based biotech and preclinical contract research organization (CRO) recognized with an XPRIZE award, specializing in scalable solutions for the preclinical evaluation of novel therapeutic targets through advanced genetically engineered in vivo models. The company utilizes cutting-edge gene editing and RNA interference (RNAi) technologies to develop human models of disease, advancing research in human health. With a focus on providing high-quality animal and cell models for in vivo studies, Mirimus empowers researchers by designing custom translatable models featuring potent reversible gene silencing. Their innovative offerings include customizable RNAi and CRISPR Cas9 mouse and rat models, as well as clinically relevant 3D tissue cultures developed from induced pluripotent stem cells (iPSCs). Generated from the website

Eterna Therapeutics, based in New York, NY, is a pioneering biotech company focused on unlocking the potential of cell engineering for curative and transformative therapies. With over 100 patents developed over the last 12 years, Eterna collaborates with life sciences companies in areas such as cell reprogramming, gene editing, and gene delivery using their proprietary mRNA technology. Specializing in rare diseases, autoimmune diseases, and oncology, Eterna not only licenses its extensive patent portfolio but also strives to develop therapeutic candidates. Recent announcements include the appointment of Peter Cicala to its board of directors and the induction of Sanjeev Luther as the new President and CEO. Generated from the website